Arterial peak enhancement on contrast-enhanced CT (CECT) images is thought to be higher in patients with low cardiac function. Using computer simulations, we tested the hypothesis that the relationship between the cardiac index and the aortic peak CT number (PCTN) is affected by the contrast material (CM) injection duration. We created computer simulation software for the contrast enhancement of various organs and vessels based on the Bae pharmacokinetics model and implemented models for CM transmission within organs and CM diffusion in blood plasma based on the osmotic pressure. Aortic contrast enhancement at coronary- and abdominal CT angiographs (CTA) was simulated for a representative 60-year-old Japanese male 166 cm in height and 65.0 kg in weight. The injection protocol for coronary CTA was: CM dose 45.5 ml, iodine dose, 245 mg/kg body weight (BW); injection duration 8-20 sec in 2-sec increments. For abdominal CTA it was CM dose 74.3 ml; iodine dose 400 mg/kg BW; injection duration 10-40 sec in 5-sec increments. In both protocols the iodine concentration was 350 mgI/ml, osmotic pressure was 590 mOsm/kgH2O, and the cardiac index ranged from 0.1-6.0 l/min/m2. Under all protocols, the aortic PCTN increased as the injection duration decreased and as the cardiac index rose to the cardiac index value. It then decreased as it exceeded the cardiac index value. At coronary CTA, at an injection duration of 8 or 10 sec, the PCTN exceeded 350 Hounsfield units (HU) at a cardiac index from 0.9-5.6 l/min/m2. At an HU value greater than 350, the range of the cardiac index narrowed when the injection duration was 12 sec or longer. On abdominal CTA scans performed with an injection duration of 10-, 15-, or 20 sec, the PCTN exceeded 350 HU at a cardiac index ranging from 0.4-5.3 l/min/m2. When the injection duration ranged from 25-40 sec, there was narrowing of the range of the cardiac index at which the PCTN exceeded 350 HU. For coronary and abdominal CTA, contrast enhancement protocols with shorter injection durations yield a diagnostically adequate aortic PCTN at a wide range of cardiac indices.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825030 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191347 | PLOS |
Indian J Orthop
January 2025
Department of Orthopaedics, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh 201310 India.
Background: Bone marrow aspirate concentrate (BMAC) is considered one of the biological treatments for knee osteoarthritis (KOA). Patient selection remains a key factor to ensure that optimal treatment benefit and body mass index (BMI) are one of the key factors to be considered. This study aims to evaluate the influence of obesity on the duration of treatment benefit of BMAC for KOA.
View Article and Find Full Text PDFInt J Nanomedicine
December 2024
Department of Plastic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Purpose: Successful regeneration of cranial defects necessitates the use of porous bone fillers to facilitate cell proliferation and nutrient diffusion. Open porous microspheres, characterized by their high specific surface area and osteo-inductive properties, offer an optimal microenvironment for cell ingrowth and efficient ossification, potentially accelerating bone regeneration.
Materials And Methods: An in vitro investigation was conducted to assess the physicochemical properties, porosity, and biocompatibility of PHA-nano-clay open porous microspheres.
J Control Release
December 2024
John A Paulson School of Engineering & Applied Sciences, Allston, MA 02134, USA; Wyss Institute of Biologically Inspired Engineering, Boston, MA 02215, USA. Electronic address:
Despite the success of global vaccination campaigns, vaccine access in low-resource settings is an ongoing challenge. Subunit vaccines are a well-established and clinically scalable intervention, yet they have achieved limited success for poorly immunogenic antigens such as those associated with SARS-CoV-2. Delivery strategies that promote gradual release of subunit vaccines from the injection site offer the potential to improve humoral immunity by enhancing lymph node exposure, however, clinical implementation of this strategy is challenging due to poor scalability and high costs.
View Article and Find Full Text PDFInt J Pharm
December 2024
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA. Electronic address:
Poly(DL-lactide-co-glycolide) (PLGA) and N-methyl-2-pyrrolidone (NMP)-based in situ forming implants are liquid formulations that solidify through phase separation following injection into the body. Drug is dissolved or suspended in the final formulation liquid prior to injection. Depending on the polymers used, the depots formed can deliver drug over different periods of time.
View Article and Find Full Text PDFZh Nevrol Psikhiatr Im S S Korsakova
December 2024
GUTA-CLINIC LLC, Moscow, Russia.
Objective: Evaluation of the safety and effectiveness of Relatox, botulinum toxin type A in patients with focal spasticity (FS) of the upper limb as a result of a cerebrovascular accident (CVA) or traumatic brain injury (TBI).
Material And Methods: A multicenter, prospective, single-blinded, randomized, comparative clinical study included 210 patients of both sexes aged 18-75 years after moderate to severe TBI and CVA in seven sites in the Russian Federation. The patients were randomized into two groups.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!